Nepal’s Department of Drug Administration (DDA) has cancelled the production, distribution and import approvals for 47 types of immunosuppressant medicines that do not have dedicated manufacturing facilities. In a public notice, the department said the approvals were revoked after the validity period of an earlier notice related to risk assessment expired. The decision was made at the director general level on